| Name | AstraZeneca |
|---|---|
| Epic | AZN |
| Isin | GB0009895292 |
| Index | UK100 UK350 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 10,502.00p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £162,812.91 | Debt ratio | n/a |
| Shares in issue | 1,550.26 | Debt-to-equity ratio | n/a |
| P/E ratio | 34.3 | Assets / equity ratio | n/a |
| Total dividends per share | 290.00¢ | Price to book value | n/a |
| Dividend yield | 2.2 | ROCE | 60.06 |
| Dividend cover | 1.32 | EPS growth | 81 |
| Earning per share | 384 | 52-week high / low | 9,501.00p / 13,276.00p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| 2nd Interim | 2024-02-22 | 2024-03-25 | 197.00¢ |
| 1st Interim | 2023-08-10 | 2023-09-11 | 93.00¢ |
| 2nd Interim | 2023-02-23 | 2023-03-27 | 197.00¢ |
| 1st Interim | 2022-08-11 | 2022-09-12 | 93.00¢ |
| 2nd Interim | 2022-02-24 | 2022-03-28 | 197.00¢ |
| 1st Interim | 2021-08-12 | 2021-09-13 | 90.00¢ |
| 2nd Interim | 2021-02-25 | 2021-03-29 | 190.00¢ |
| 1st Interim | 2020-08-13 | 2020-09-14 | 90.00¢ |
| 2nd Interim | 2020-02-27 | 2020-03-30 | 190.00¢ |
| Company name | AstraZeneca |
|---|---|
| Address | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge,United Kingdom, CB2 0AA |
| Telephone | +44 (0)20 3749 5000 |
| Website | http://www.astrazeneca.com |
| Director | Position |
|---|---|
| Mr Michel Demare | Chairman |
| Mr Marcus Wallenberg | Non-Executive Director |
| Ms Anna Manz | Non-Executive Director |
| Mr Andreas Rummelt | Non-Executive Director |
| Mr Philip A J Broadley | Senior Independent Non-Executive Director |
| Mr Tony Mok | Independent Non-Executive Director |
| Mrs Deborah DiSanzo | Independent Non-Executive Director |
| Ms Diana Layfield | Independent Non-Executive Director |
| Mrs Nazneen Rahman | Independent Non-Executive Director |
| Mrs Sheri McCoy | Independent Non-Executive Director |
| Dr Euan Ashley | Independent Non-Executive Director |
| Mr Pascal Soriot | CEO and Executive director |
| Dr Aradhana Sarin | CFO & Executive Director |
| Assets $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Reporting date | 31/12/23 | 31/12/22 | 31/12/21 |
| Intangible asssets and goodwill | 58137 | 59127 | 62384 |
| Investments and other non-current assets | 1677 | 1142 | 1237 |
| Total non-current assets | 76065 | 73890 | 79119 |
| Inventory / work in progress | 5424 | 4699 | 8983 |
| Trade and other receivables | 13552 | 11252 | 10307 |
| Cash and equivalents | 5840 | 6166 | 6329 |
| Other current assets and asset held for resale | 116 | 87 | 556 |
| Total of all assets | 101119 | 96483 | 105363 |
| Liabilities $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Short term liabilities | 30542 | 26293 | 22594 |
| Long term liabilities | 31411 | 33132 | 43482 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 61953 | 59425 | 66076 |
| Net assets $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Net assets | 39166 | 37058 | 39287 |
| Equity $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Share capital | 388 | 387 | 387 |
| Minority interests | 23 | 21 | 19 |
| Retained earnings | 1502 | -574 | 1710 |
| Share premium account | 35188 | 35155 | 35126 |
| Total equity | 39166 | 37058 | 39287 |
| Income $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | 8193 | 3757 | 1056 |
| Pre-tax profit | 6899 | 2501 | -265 |